SML2883

Paquinimod

≥98% (HPLC), powder, immunomodulator

• Synonym(e): ABR 215757, ABR 25757, ABR-215757, ABR-25757, ABR215757, ABR25757, N,5-Diethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide, N-Ethyl-N-phenyl-1,2-dihydro-5-ethyl-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide, N-Ethyl-N-phenyl-5-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide
• Empirische Formel (Hill-System): C₂₁H₂₂N₂O₃
• CAS-Nummer: 248282-01-1
• Molekulargewicht: 350.41
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD18633277
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: Paquinimod, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: N1(c2c(c(ccc2)CC)C(=O)C(C1=O)C(=O)N(CC)c3ccccc3)C
• InChI: 1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,18H,4-5H2,1-3H3
• InChI key: RBHDLRDFJPBLNO-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

Orally active S100A9 (Calgranulin B; MRP14) blocker with in vivo efficacy in murine models of autoimmune diseases.

Paquinimod (ABR-215757) is an orally active quinoline-3-carboxamide (Q substance) class immunomodulator that targets S100A9 (Calgranulin B; MRP14) via direct binding and blocks its interaction with receptor for advanced glycation end products (RAGE) and Toll-like receptor 4 (IC₅₀ = 26 μM & 23 μM against 100 nM hS100A9 from binding immobilized hRAGE & hTLR4/MD2, respectively). Paquinimod in vivo efficacy is demonstrated in murine models of autoimmune/inflammatory diseases, including liver fibrosis, collagen-induced osteoarthritis, peritonitis, EAE, type 1 diabetes, lupus (0.04-25 mg/kg/day p.o.), and atherosclerosis (10 mg/kg i.p.).

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable